Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
- Written by PR Newswire
 |
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant step towards commercialization by demonstrating...
